GlutenSwitch App
GlutenSwitchGlutenSwitch helps people living with coeliac disease or a gluten intolerance to identify alternatives that are both gluten-free and similar in healthiness to the scanned item.We have recently launched a new standalone app called GlutenSwitch with added features to help people find foods that are both declared gluten-free by the manufacturer and also foods that we have estimated as gluten-free based on their ingredients. We have also introduced a new feature that allows the user to select the store they are in to show choices that are likely available in their location.The GlutenSwitch app is available in Australia:GlutenSwitch Australia - [Android] [iOS] FAQsWhat is GlutenSwitch?GlutenSwitch will give you the gluten status of a product, based on if the product is declared gluten-free by the manufacturer or that we have estimated as gluten-free based on their ingredients. GlutenSwitch will also list similar foods that are declared gluten-free and estimated gluten free. You can access th
Policy and legal review of organ transplantation in six countries
BackgroundGlobal regulatory frameworks such as the WHO Guiding Principles on Human Organ Transplantation (1991) and the Declaration of Istanbul on Organ Trafficking and Transplant Tourism (2008, 2018), formulated by professional organisations led by The Transplantation Society (TTS) and the International Society of Nephrology (ISN), provide an ethical framework for organ transplantation to combat the universal shortage of organs, organ trafficking, financial inducements, and coercion in donation.While these global principles, coupled with domestic regulatory landscapes, have had positive impacts, unethical practices continue to be reported, especially from low- and middle-income countries.AimTo identify the intersection of international ethics principles and guidelines with the domestic regulatory frameworks of select developing countries.To understand the barriers and facilitators to the implementation of international ethics principles and guidelines in the domestic laws and policies of select developing co
Submission to Australian Parliament's Human Rights Sub-Committee on women and girls in the Pacific
Policy & Practice Report
Responding to UK DHSC’s Women’s Health Strategy Call for Evidence
Policy & Practice Report
ASPIrin to Reduce Events in Dialysis (ASPIRED)
The ASPIRED Trial will determine the safety and efficacy of low dose aspirin for the prevention of cardiovascular events in people with end stage kidney disease receiving dialysis.
Introducing a total online advertising restriction for products high in fat, sugar, and salt
Policy & Practice Report
Health and Well-being of Waste Workers in India
Policy & Practice Report
Primary Health Reform – Response to the Recommendations by The George Institute
Policy & Practice Report
Submission to the Senate inquiry on definitions of meat and other animal products
Policy & Practice Report
Food is Medicine: developing a Medically-Tailored Meal (MTM) program to tackle type 2 diabetes and heart disease in Australia
Eating an unhealthy diet is a leading risk factor for chronic diseases worldwide. Innovative new programs to improve the diet of millions of Australians at high risk of heart disease, such as those with high blood pressure and type 2 diabetes (T2D), have tremendous potential to save lives and reduce healthcare costs.
The George Institute and partners call for recognition of unheard voices at the UN Food Systems Summit
Policy & Practice Report
Understanding the economics of Tuberculosis (TB) patients in the private sector
Background
Despite free treatment offered by the government, the private sector plays a significant role in Tuberculosis (TB) treatment in India. The reasons for availing private facilities are dissatisfaction with public sector services, non-availability of public facilities in the neighbourhood, long waiting time etc. A literature review identified that only three studies (covered total of 102 patients) estimated the cost for the TB patients treated in the private sector. Two studies considered only multi-drug resistant TB patients, the third one collected out of pocket expenses data from a convenient sample of 32 drug susceptible TB patients. Therefore, there is a clear dearth of data on the economic burden of TB in the private sector in India.
Aim
The national strategic plan for TB (2017-2025) stated its intention to extend the umbrella of high-quality TB care and control to those treated in the private sector, highlighting private sector engagement (PPE) as an important strategy to eliminate TB.
